1.76 USD
+0.03 (+1.73%)
1.77 USD
+0.01 (+0.57%)
ChartMill assigns a Buy % Consensus number of 80% to INO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.79. This target is 342.38% above the current price.
INO was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about INO.
In the previous month the buy percentage consensus was at a similar level.
INO was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-08-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-07-09 | Piper Sandler | Initiate | Overweight |
| 2025-05-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-14 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-03-19 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-14 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-13 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-01-10 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-18 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-11-15 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-08-12 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-08-09 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-07-15 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-05-14 | Stephens & Co. | Initiate | Overweight |
| 2024-03-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-03-07 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-01-25 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-01-04 | JMP Securities | Initiate | Market Outperform |
| 2023-05-11 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2023-03-02 | RBC Capital | Maintains | Sector Perform |
| 2022-11-09 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-11-01 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2022-08-10 | RBC Capital | Maintains | Sector Perform |
| 2022-05-11 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-03-02 | RBC Capital | Maintains | Sector Perform |
| 2022-01-21 | B of A Securities | Upgrade | Underperform -> Neutral |
INOVIO PHARMACEUTICALS INC / INO FAQ
What do analysts expect the price target to be for INOVIO PHARMACEUTICALS INC (INO)?
10 analysts have analysed INO and the average price target is 7.79 USD. This implies a price increase of 342.38% is expected in the next year compared to the current price of 1.76.
Can you provide the consensus rating for INOVIO PHARMACEUTICALS INC stock?
The consensus rating for INOVIO PHARMACEUTICALS INC (INO) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for INO stock?
The number of analysts covering INOVIO PHARMACEUTICALS INC (INO) is 10.